BeOne Medicines shared a post on LinkedIn:
“News for Investors and Media: The FDA has granted our GPC3x4-1BB bispecific antibody Fast Track Designation in hepatocellular carcinoma (HCC), which accounts for 80% of all primary liver cancers. HCC is the sixth most common cancer worldwide and the fourth leading cause of cancer-related death. With the number of new cases expected to double between 2022 and 2050, new treatment options are needed, especially in advanced stages of the disease.
Learn more about the Fast Track Designation from Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne.
Proceed to the video attached to the post.
More posts featuring BeOne Medicines.